SNPMiner Trials: Mutation Report

---

Report for Mutation T351I

Developed by Shray Alag, 2019.

SNP Clinical Trial Gene

There is one clinical trial.

Clinical Trials

---

1 Allogeneic Hematopoietic Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

This study is being done to learn whether a new method to prevent rejection between the donor immune system and the patient's body is effective.

NCT03615105 Acute Lymphoid Leukemia (ALL) Acute Myeloid Leukemia (AML) Chronic Myeloid Leukemia (CML) Hodgkin Lymphoma Non-Hodgkin Lymphoma Chronic Lymphocytic Leukemia Radiation: Hyperfractionated total body irradiation Drug: Thiotepa Drug: Cyclophosphamide Drug: Busulfan Drug: Fludarabine Drug: Melphalan Drug: Clofarabine Procedure: HPC(A) stem cell allograft Drug: Rituximab Device: Rabbit antithymocyte globulin

MeSH: Lymphoma Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Lymphoma, Non-Hodgkin Leukemia, Lymphoid Leukemia, Lymphocytic, Chronic, B-Cell Hodgkin Disease Leukemia, Myelogenous, Chronic, BCR-ABL Positive Precursor Cell Lymphoblastic Leukemia-Lymphoma

HPO: Acute megakaryocytic leukemia Acute myeloid leukemia Chronic lymphatic leukemia Chronic myelogenous leukemia Hodgkin lymphoma Leukemia Lymphoid leukemia Lymphoma Myeloid leukemia Non-Hodgkin lymphoma

T351I mutation). --- T351I ---

Primary Outcomes

Description: The intervention will be considered unpromising if the rate of GVHD is greater than 40% and promising if the rate is 20% or less.

Measure: the number of incidences of grade 3-4 acute GVHD

Time: 2 years

---

---

HPO Nodes

---

Leukemia

Genes 125

MPL RNASEH2B KRAS NPM1 TET2 MYD88 TSR2 RPL26 RPL27 TREX1 EFL1 PIGL SCN11A FLT3 PMS2 RPL35A EVC2 ABL1 CEBPA RARA NRAS WAS WIPF1 ATRX SH2B3 PDGFRA RB1 RNASEH2A PDGFRB CALR ARHGAP26 SH3GL1 RPS7 RPS10 NUMA1 GATA1 GATA2 RPS15A APC NSD1 ETV6 TCIRG1 DNAJC21 EVC SRP54 RPS17 NBN RPS19 SAMHD1 MSH2 RPS24 NUP214 RPS26 RPS27 RPS28 RPS29 MLLT10 RUNX1 XRCC4 CBFB CBL BCR ADAR TRIP13 ADA2 NSUN2 CREBBP PICALM GFI1 F13A1 F13B FANCA FANCC BLM FANCD2 FANCE NUTM1 JAK2 IFIH1 TYROBP MSH6 FANCG LIG4 PTPN11 SAMD9L THPO NF1 STS PIGA BRCA2 DYNC2LI1 PIK3CA SBDS GLI1 PIK3R1 BRD4 SETBP1 RNASEH2C LPP BUB1 BUB1B SCN9A SCN10A TREM2 MLF1 MLH1 ELANE DKC1 ATM HAX1 RPL35 GNB1 BUB3 CEP57 TAL1 KIT TAL2 RPL5 EP300 TP53 RPL11 KIF11 RPL15 DNMT3A RPL18

Hodgkin lymphoma

Genes 12

POLE FAS FASLG AAGAB ATM DKC1 CASP10 PRKCD RASGRP1 TCF4 COL14A1 RNF43

Non-Hodgkin lymphoma

Genes 22

MYC FAS ADA FASLG IGH KIT BIRC3 CASP10 NBN CD28 MALT1 PRKCD RASGRP1 FOXP1 PIK3R1 NTHL1 POLE CCND1 BCL10 CTLA4 ATM TNFRSF1B

Acute myeloid leukemia

Genes 29

MPL MLF1 NSD1 JAK2 KRAS NPM1 ELANE DKC1 ETV6 TCIRG1 DNAJC21 SRP54 EFL1 FLT3 NUP214 CEBPA THPO MLLT10 RUNX1 PIGA CBFB BRCA2 KIT PICALM SBDS GFI1 SH3GL1 LPP DNMT3A

Chronic lymphatic leukemia

Genes 8

SAMHD1 RNASEH2B ADAR RNASEH2A IFIH1 RNASEH2C TREX1 PIK3R1

Chronic myelogenous leukemia

Genes 5

MPL BCR JAK2 KIT THPO

Lymphoid leukemia

Myeloid leukemia

Genes 12

GATA2 F13A1 CBL ARHGAP26 F13B KRAS PTPN11 SAMD9L KIT SETBP1 NF1 NRAS

Lymphoma

Genes 94

BLM MYC CDKN2A KRAS MYD88 RMRP RAG1 RAG2 MALT1 MSH6 RASGRP1 LIG4 TCF4 PMS2 ICOS NRAS WAS WIPF1 CD19 MS4A1 USB1 IGH TINF2 RB1 DCLRE1C TNFSF12 RTEL1 CTC1 CD27 CD28 PIK3R1 PRF1 NTHL1 TP63 POLE HLA-DRB1 NFKB1 NFKB2 RECQL4 RAD54B CHEK2 TNFRSF13C APC MLH1 TNFRSF13B DKC1 BIRC3 XIAP CASP10 NBN PRKCD COL14A1 FOXP1 CD81 PARN NOP10 CCND1 BCL10 BCL2 MSH2 CHD7 CTLA4 ATM BCL6 MAGT1 RUNX1 TNFRSF1B XRCC4 WRAP53 PTEN MDM2 FAS NHP2 ADA FASLG CR2 SH2D1A TERC AAGAB KIT TERT NSUN2 IL2RG LYST RNF43 ZAP70 DNASE1L3 TP53 RAD54L ITK STAT3 IL7R KIF11 PNP